A placebo-controlled, randomized, double-blind phase II clinical study of Gammagard intravenous immunoglobulin (IVIg) for treatment of mild to moderate Alzheimer's disease

Trial Profile

A placebo-controlled, randomized, double-blind phase II clinical study of Gammagard intravenous immunoglobulin (IVIg) for treatment of mild to moderate Alzheimer's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jul 2012 Long-term follow-up results presented at the 2012 International Conference on Alzheimer's Disease.
    • 17 Jul 2012 Three year extension results were presented at the Alzheimer's Association International Conference 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top